Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences reported one-year Phase 2 and open-label extension data for once-weekly canvuparatide in adults with chronic hypoparathyroidism. In the 12-week Avail trial, 63% of canvuparatide-treated patients (30/48) met the primary composite endpoint versus 31% on placebo (5/16), showing better control of calcium with reduced dependence on supplements. At one year, 57% of evaluable patients (31/54) were responders with no rescue therapy used in the final week, and 90% of patients entering the extension remained on treatment, indicating strong durability and retention.
Pharmacokinetic data showed a Tmax of 2–3 days and a peak‑to‑trough ratio around 1.3, supporting stable once-weekly dosing. Mean serum calcium stayed in the normal range while 24‑hour urine calcium fell and remained normal, kidney function (eGFR) improved, and bone turnover markers and bone mineral density shifted in patterns consistent with physiologic PTH replacement. Canvuparatide was generally well tolerated through one year, with most adverse events mild or moderate, no treatment-related serious events, and injection site reactions in 10% of patients. MBX plans to start a Phase 3 pivotal trial in Q3 2026 and reports about $440 million in cash, cash equivalents and marketable securities as of March 31, 2026, which it estimates will fund operations into 2029.
Richard B. Bartram reported a proposed sale of 9,167 shares of Common Stock related to a stock option exercise, planned for 06/10/2026 and to be processed through Fidelity Brokerage Services LLC on NASDAQ for cash. The filing also lists multiple open-market dispositions by Mr. Bartram during the prior three months, including sales on 05/11/2026 (22,500 shares) and 06/09/2026 (10,833 shares).
MBX officer reported proposed sales of common stock under Form 144 related to stock option exercises and prior open-market dispositions. The filing lists multiple sales and proposed sale activity, including individual transactions on 03/16/2026, 03/25/2026, 04/22/2026, and several dates in May and June 2026.
MBX Biosciences director Edward T. Mathers received a new stock option grant covering 12,500 shares of common stock. The option has an exercise price of $30.91 per share and expires on June 4, 2036. Following this grant, he holds 12,500 stock option rights directly.
The grant vests in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual meeting of stockholders, as long as he continues serving as a non-employee director.
MBX Biosciences director Ora H. Pescovitz received a grant of stock options, reflecting equity-based compensation rather than an open-market trade. The award covers 12,500 options to buy common stock at an exercise price of $30.91 per share, expiring on June 4, 2036.
According to the terms, the grant will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual stockholder meeting, subject to her continued service as a non-employee director. Following this filing, she also holds 24,329 shares of common stock directly.
MBX Biosciences, Inc. director and ten percent owner Patrick J. Heron received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.91 per share and expire on June 4, 2036.
The grant will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual meeting of stockholders, as long as the non-employee director continues to provide services. This is a compensation-related award rather than an open-market share purchase or sale.
MBX Biosciences, Inc. director Laurie Stelzer received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.91 per share and expire on June 4, 2036.
According to the terms, the grant will vest in full on the earlier of the one-year anniversary of the June 4, 2026 grant date or the date of the company’s next annual meeting of stockholders, as long as Stelzer continues to serve as a non-employee director. Following this award, Stelzer holds options for 12,500 shares directly.
MBX Biosciences director Steven L. Hoerter received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.9100 per share and expire on June 4, 2036. According to the footnotes, the grant will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual meeting of stockholders, as long as he continues serving as a non-employee director.
After these transactions, Hoerter is reported as holding 11,938 shares of common stock directly and 20,000 shares indirectly through the Steven L Hoerter Revocable Trust dated November 2, 2018, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
MBX Biosciences director Steven Ryder received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.91 per share and were awarded at no cost as a compensation grant.
The award vests in full on the earlier of the one-year anniversary of the grant date or the company’s next annual stockholder meeting, as long as Ryder continues serving as a non-employee director. After this grant, he holds options for 12,500 underlying shares, which expire on June 4, 2036.
MBX Biosciences, Inc. director Tiba Aynechi received a grant of stock options covering 12,500 shares of common stock as equity compensation. The options have an exercise price of $30.91 per share and expire on June 4, 2036. The grant will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders, as long as the non-employee director continues to serve.